Stargardt Syndrome

Both conditions damage the macula, but Stargardt syndrome usually starts in late childhood or the teen years and is driven by a recessive genetic mutation, while AMD typically develops after age 55 and involves multiple genetic and environmental factors.

There is no FDA-approved cure yet. Current care focuses on protecting remaining vision, using low-vision aids, and monitoring emerging treatments such as gene therapy, stem-cell therapy, and complement inhibitors in clinical trials.

Protecting eyes from strong sunlight, eating a diet rich in leafy greens and omega-3 fatty acids, avoiding smoking, and managing overall health may help reduce additional retinal stress, though they cannot stop the genetic process.

High-dose vitamin A palmitate is generally discouraged because it can increase toxic by-products in ABCA4-related disease. Always consult your eye-care provider before starting any supplement regimen.

It follows an autosomal recessive pattern—both parents must carry one faulty ABCA4 gene copy for their child to be affected. Each pregnancy has a 25 percent chance of producing an affected child when both parents are carriers.

Yes. Studies investigating gene replacement therapies, novel vitamin A analogs, and stem-cell-based retinal repair are ongoing. Ask your retina specialist or visit ClinicalTrials.gov to see if you qualify for a study.